Compare FRO & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRO | INDV |
|---|---|---|
| Founded | 1985 | N/A |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.4B |
| IPO Year | 1995 | 2014 |
| Metric | FRO | INDV |
|---|---|---|
| Price | $37.99 | $40.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $37.67 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 1.6M |
| Earning Date | 05-22-2026 | 06-08-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $34.05 | $59.86 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $18.04 | $15.00 |
| 52 Week High | $43.10 | $42.81 |
| Indicator | FRO | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 57.41 |
| Support Level | $33.79 | $35.36 |
| Resistance Level | $39.73 | $41.00 |
| Average True Range (ATR) | 1.77 | 1.56 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 41.69 | 55.32 |
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).